Article
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors.
Cancer research - 15 Oct 2024
Cadzow Louise, Brenneman Jehrod, Tobin Erica, Sullivan Pamela, Nayak Sumeet, Ali Janid A, Shenker Sol, Griffith Jim, McGuire Michael, Grasberger Paula, Mishina Yuji, Murray Morgan, Dodson Anne E, Gannon Hugh, Krall Elsa, Hixon Jeff, Chipumuro Edmond, Sinkevicius Kerstin, Gokhale Prafulla C, Ganapathy Suthakar, Matulonis Ursula A, Liu Joyce F, Olaharski Andrew, Sangurdekar Dipen, Liu Hanlan, Wilt Jeremy, Schlabach Michael, Stegmeier Frank, Wylie Andrew A
Abstract excerpt
Defects in DNA repair pathways play a pivotal role in tumor evolution and resistance to therapy. At the same time, they create vulnerabilities that render tumors dependent on the remaining DNA repair processes. This phenomenon is exemplified by the clinical activity of PARP inhibitors in tumors with homologous recombination (HR) repair defects, such as tumors with inactivating mutations in BRCA1 or BRCA2....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.